Agenus Inc. (NASDAQ: AGEN) presented Phase 2 trial data for its drug combination botensilimab and balstilimab in patients with advanced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE